# Semaglutide en tirzepatide vergelijkbaar bij cardiovasculair risicopatiënten zonder diabetes — TriNetX-analyse

*geplaatst 2026-11-22 · Hartfalen · American heart journal plus : cardiology research and practice · doi 10.1016/j.ahjo.2026.101003 · https://hartvaat.nl/2026/12/01/semaglutide-en-tirzepatide-vergelijkbaar-bij-cardiovasculair-risicopatienten-zon/*

In een retrospectieve, propensity score-gematchte cohortstudie van TriNetX werden 11.330 volwassenen met obesitas en ASCVD zonder diabetes vergeleken bij start van semaglutide of tirzepatide. Na matching waren er geen significante verschillen in 5-punts MACE (19,5% vs 17,1%; HR 1,03; 95% BI 0,94-1,12) of 3-punts MACE (17,4% vs 15,4%; HR 1,04; 95% BI 0,95-1,14). Deze real-world data suggereren vergelijkbare cardiovasculaire effectiviteit, maar prospectieve head-to-head trials zijn nodig om de bevindingen definitief te valideren.

## English: Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes.

A propensity score-matched retrospective cohort study using the TriNetX database compared 11,330 adults with obesity and ASCVD but no diabetes initiating semaglutide or tirzepatide. There were no significant differences between the two agents for 5-point MACE (19.5% vs 17.1%; HR 1.03; 95% CI 0.94–1.12) or 3-point MACE (17.4% vs 15.4%; HR 1.04; 95% CI 0.95–1.14). These real-world findings suggest comparable cardiovascular efficacy, underscoring the need for prospective head-to-head trials to validate the results and inform future prescribing.

## Abstract (original, from the publication)

BACKGROUND: Comparative cardiovascular data on glucagon-like peptide-1 (GLP-1) agonists versus dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists in atherosclerotic cardiovascular disease (ASCVD) without diabetes are limited. METHODS: This propensity score-matched retrospective TriNetX study compared adults aged ≥45 years with body mass index ≥27 kg/m2 and ASCVD initiating treatment with semaglutide or tirzepatide. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to analyze 3-point major adverse cardiovascular events (MACE: all-cause mortality, myocardial infarction, or ischemic stroke) and 5-point MACE (3-point MACE plus heart failure exacerbation and revascularization). RESULTS: After matching, 5665 patients were analyzed per group. No statistically significant differences were observed between semaglutide and tirzepatide in 5-point MACE (19.5% vs 17.1%; HR 1.03; 95% CI 0.94-1.12), 3-point MACE (17.4% vs 15.4%; HR 1.04; 95% CI 0.95-1.14), or any individual component. CONCLUSIONS: Semaglutide and tirzepatide were associated with similar cardiovascular outcomes. Prospective head-to-head trials are warranted to validate these results.

Auteurs: Mohamed Doma, Adham Ramadan, Mohammad Hosein Yazdanpanah, Farhan Naeem, Leon M Ptaszek, Jeremy N Ruskin

---
Bron: American heart journal plus : cardiology research and practice, https://doi.org/10.1016/j.ahjo.2026.101003. Bijgewerkt 2026-11-15T02:27:26Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.
